NACDS letter to the editor: Pharmacists can help improve medication adherence
ARLINGTON, Va. — The National Association of Chain Drug Stores on Friday released a response to a Sept. 5 article in The Washington Post about efforts to improve medication adherence through research and patient-focused strategies.
In its letter to the editor, NACDS stated:
“[The article] ’Researchers are trying again to help you take your medicine’ hit the nail on the head about the importance of patients taking their medication as prescribed. Researchers interviewed for the article indicate that medication adherence will not improve 'if patients don't develop the habit of sticking to their medication regimens.'
"But there is a solution.
"Pending bipartisan legislation in the U.S. Senate — S. 776, the Medication Therapy Management Empowerment Act of 2015 — would improve access to medication therapy management services for senior citizens enrolled in the Medicare program. Medicare Part D patients with specific chronic conditions — diabetes, cardiovascular disease, COPD and high cholesterol — would benefit from the education and training of pharmacists and other qualified health practitioners to help ensure that medications are taken appropriately.
"There is overwhelming support and research — including the Centers for Medicare and Medicaid Services and the Congressional Budget Office — showing that filling prescription medications and taking them as prescribed improves medication adherence, resulting in better health outcomes and reduced overall medical costs.
"Continued nonadherence will only generate greater health risks for patients with chronic conditions. This commonsense legislation is key to improving medication adherence and health for these patients."
FDA approves two new diabetes drug treatments
SILVER SPRINGS, Md. — The Food and Drug Administration on Friday approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar control in adults with diabetes mellitus. Both Tresiba and Ryzodeg are manufactured by Novo Nordisk.
"Long-acting insulins play an essential role in the treatment of patients with Type 1 diabetes and in patients with Type 2 diabetes with advanced disease," said Jean-Marc Guettier,bdirector of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research.
Tresiba is a long-acting insulin analog indicated to improve glycemic control in adults with Type 1 and Type 2 diabetes mellitus, with dosing based on the patient’s needs. Tresiba is administered subcutaneously once daily. In clinical trial participants with Type 1 and Type 2 diabetes who had inadequate blood sugar control at trial entry, treatment with Tresiba provided reductions in HbA1c in line with reductions achieved with other long-acting insulin.
Ryzodeg 70/30 is a mixture of insulin degludec, a long-acting insulin analog, and insulin aspart, a rapid-acting human insulin analog. It is indicated to improve glycemic control in adults with diabetes mellitus. In clinical trial participants with Type 1 and Type 2 diabetes who had inadequate blood sugar control at trial entry, treatment with Ryzodeg 70/30 provided reductions in HbA1c equivalent to reductions achieved with other long-acting or pre-mixed insulin.
According to the FDA, Tresiba and Ryzodeg should not be used in those who have increased ketones in their blood or urine. The most common adverse reactions associated with Tresiba and Ryzodeg in clinical trials were hypoglycemia, allergic reactions, injection site reactions, pitting at the injection site (lipodystrophy), itching, rash, edema, and weight gain.
According to the Centers for Disease Control and Prevention, approximately 21 million people in the United States have been diagnosed with diabetes.
Mylan comments on Perrigo lawsuit
HERTFORDSHIRE, England, and PITTSBURGH — In the latest on the Mylan bid for Perrigo, Mylan on Thursday released a statement about the Perrigo lawsuit filed in Israel on Thursday.
The statement read:
“Mylan believes that the Perrigo suit filed in Israel [Thursday] is entirely without merit and that Mylan's offer in Israel is valid and proper in all respects.
“With that said, Perrigo's efforts are entirely futile, as all Perrigo shareholders — institutional and retail, including those in Israel — have always been free to switch their holdings at any time from the Tel Aviv Stock Exchange to the New York Stock Exchange, through a simple, fully automated, well-established system by notifying their broker. As a result, shareholders can participate fully in Mylan's compelling offer without regard to any lawsuits in Israel or any other frustrating actions pursued by Perrigo in Israel.
“Further, as Mylan has previously stated publicly, it has been our intent and desire to list Mylan's shares on the TASE to maintain liquidity in Israel for the convenience of those shareholders in Israel who prefer to trade on the TASE, and Mylan is already well-advanced in the process of submitting its application to the TASE and the Israel Securities Authority, and is committed to continuing to work closely with these parties to complete this process.”